BLTE vs. PRTA, GYRE, IRWD, SYRE, PCRX, LGND, MIRM, COLL, GMTX, and MNKD
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Prothena (PRTA), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Spyre Therapeutics (SYRE), Pacira BioSciences (PCRX), Ligand Pharmaceuticals (LGND), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), Gemini Therapeutics (GMTX), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio (NASDAQ:BLTE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Prothena received 580 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.24% of users gave Belite Bio an outperform vote while only 70.67% of users gave Prothena an outperform vote.
Belite Bio has higher earnings, but lower revenue than Prothena. Belite Bio is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Belite Bio currently has a consensus price target of $44.83, suggesting a potential upside of 6.62%. Prothena has a consensus price target of $67.00, suggesting a potential upside of 213.96%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Belite Bio.
In the previous week, Prothena had 8 more articles in the media than Belite Bio. MarketBeat recorded 17 mentions for Prothena and 9 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.85 beat Prothena's score of -0.27 indicating that Belite Bio is being referred to more favorably in the media.
Belite Bio has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Belite Bio has a net margin of 0.00% compared to Prothena's net margin of -193.17%. Prothena's return on equity of -30.48% beat Belite Bio's return on equity.
0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Prothena beats Belite Bio on 10 of the 17 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
